FDA Determines Regulatory Review Period for XTAMPZA ER Patent Extension

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for XTAMPZA ER, a human drug product, following the submission of patent extension applications to the US Patent and Trademark Office (USPTO).